Health Jun 01 Mylan may have overcharged taxpayers by $1.27 billion for EpiPens, HHS says Mylan may have overcharged taxpayers as much as $1.27 billion over 10 years for its signature EpiPens, according to an analysis released Wednesday. By Ike Swetlitz, STAT
Politics Nov 21 EpiPen manufacturer will be a no-show at Senate hearing WASHINGTON — Pharmaceutical company Mylan is refusing to testify at a congressional hearing next week on a settlement between the company and the Justice Department over its life-saving EpiPen. By Mary Clare Jalonick, Associated Press
Health Sep 23 With an increase in EpiPen use among seniors, Medicare spending up 1,100 percent The total number of Medicare beneficiaries using EpiPens climbed 164 percent while Medicare spending skyrocketed nearly 1,100 percent from 2007 to 2014, a new report shows. By Julie Appleby and Mary Agnes Carey, Kaiser Health News
Economy Sep 21 Watch 3:36 News Wrap: Fed will keep key interest rate near record lows In our news wrap Wednesday, the Federal Reserve said it will hold on keeping a key, short-term interest rate near record lows. Chair Janet Yellen suggested a hike was likely before year’s end. Also, the crisis in Syria took center… By PBS News Hour
Sep 21 Mylan CEO defends EpiPen cost to angry lawmakers By Mary Clare Jalonick, Associated Press The head of pharmaceutical company Mylan is defending the cost for life-saving EpiPens, signaling the company has no plans to lower prices despite a public outcry and questions from skeptical lawmakers. Continue reading
Sep 07 Senate panel opens investigation into EpiPen price hikes By Associated Press A Senate panel has opened a preliminary investigation into why the price of lifesaving EpiPens has skyrocketed. Continue reading
Sep 06 Outcry over EpiPen highlights FDA’s long backlog of generics By Sydney Lupkin, Kaiser Health News As of July 1, the FDA had 4,036 generic drug applications awaiting approval. The FDA has approved more generics the past few years, but a flood of new applications has steadily added to the demand. Continue reading
Sep 02 Clinton offers plan to prevent ‘excessive’ drug price hikes By Catherine Lucey, Associated Press Following the public outcry over steep increases in price for an emergency allergy treatment, Hillary Clinton is pledging to better protect patients from such costs. Continue reading
Sep 01 Mylan’s generic EpiPen — a price break or marketing maneuver? By Julie Appleby, Kaiser Health News Following weeks of criticism, Mylan said Monday it will offer a generic version of its life-saving allergy treatment, the EpiPen. But what does this development mean for consumers and the marketplace?… Continue reading